Imlygic
Payments companies reported to CMS as associated with Imlygic. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Imlygic, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Imlygic
These are the largest totals companies reported as associated with Imlygic. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Yuanbin Chen | Orlando, FL | Medical Oncology | $88.24 |
| Sreenivasa Chandana | Grand Rapids, MI | Hematology & Oncology | $88.24 |
| Jorge Diaz Castro | Huntsville, AL | Hematology & Oncology | $53.26 |
| John Waples | Huntsville, AL | Medical Oncology | $53.26 |
| Saurabh Parasramka | Frankfort, KY | Medical Oncology | $27.77 |
| Tyler Mouw | Lubbock, TX | Surgical Oncology | $27.57 |
| Nathaniel Mcvey | Billings, MT | Physician Assistant | $18.89 |
| Nicole Hannigan | Oak Lawn, IL | Family | $18.89 |
| Cesar Tula | Waco, TX | Hematology & Oncology | $18.89 |
| Kristin Spence | Olive Branch, MS | Family | $15.60 |
Prescribed Imlygic?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.